Skip to main content

editorial

. 1993 Nov 13;307(6914):1223–1224. doi: 10.1136/bmj.307.6914.1223

How "malignant" is the neuroleptic malignant syndrome?

M F Bristow, D Kohen

PMCID: PMC1679364 PMID: 8281048

1223

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Adityanjee The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry. 1991 May;158:706–707. doi: 10.1192/bjp.158.5.706. [DOI] [PubMed] [Google Scholar]
Gratz S. S., Levinson D. F., Simpson G. M. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 1992 Jul;16(4):425–443. doi: 10.1016/0278-5846(92)90051-f. [DOI] [PubMed] [Google Scholar]
Gurrera R. J., Romero J. A. Sympathoadrenomedullary activity in the neuroleptic malignant syndrome. Biol Psychiatry. 1992 Aug 15;32(4):334–343. doi: 10.1016/0006-3223(92)90037-z. [DOI] [PubMed] [Google Scholar]
Kellam A. M. The neuroleptic malignant syndrome, so-called. A survey of the world literature. Br J Psychiatry. 1987 Jun;150:752–759. doi: 10.1192/bjp.150.6.752. [DOI] [PubMed] [Google Scholar]
Nisijima K., Ishiguro T. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry. 1990 Feb 1;27(3):280–288. doi: 10.1016/0006-3223(90)90002-j. [DOI] [PubMed] [Google Scholar]
O'Dwyer A. M., Sheppard N. P. The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. Psychol Med. 1993 May;23(2):323–326. doi: 10.1017/s0033291700028415. [DOI] [PubMed] [Google Scholar]
Rosebush P. I., Stewart T. D., Gelenberg A. J. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry. 1989 Aug;50(8):295–298. [PubMed] [Google Scholar]
Rosenberg M. R., Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med. 1989 Sep;149(9):1927–1931. doi: 10.1001/archinte.149.9.1927. [DOI] [PubMed] [Google Scholar]
Sewell D. D., Jeste D. V. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases. J Neuropsychiatry Clin Neurosci. 1992 Summer;4(3):265–269. doi: 10.1176/jnp.4.3.265. [DOI] [PubMed] [Google Scholar]
Shalev A., Hermesh H., Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989 Jan;50(1):18–25. [PubMed] [Google Scholar]
Weller M., Kornhuber J. A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses. 1992 Aug;38(4):329–333. doi: 10.1016/0306-9877(92)90027-a. [DOI] [PubMed] [Google Scholar]
White D. A. Catatonia and the neuroleptic malignant syndrome--a single entity? Br J Psychiatry. 1992 Oct;161:558–560. doi: 10.1192/bjp.161.4.558. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES